<DOC>
	<DOCNO>NCT02332707</DOCNO>
	<brief_summary>This randomize , three-part , open-label trial grazoprevir ( MK-5172 ) ( 100 mg ) MK-3682 ( 300 mg 450 mg ) , either elbasvir ( MK-8742 ) ( 50 mg ) ruzasvir ( MK-8408 ) ( 60 mg ) , without ribavirin ( RBV ) , treatment-naïve ( TN ) treatment-experienced ( TE ) cirrhotic ( C ) non-cirrhotic ( NC ) hepatitis C virus ( HCV ) participants chronic HCV genotype ( GT ) 1 GT2 infection . Part A consist 8 arm evaluate safety dose combination . In Part B , participant take 2 MK-3682B fix dose combination ( FDC ) tablet daily ( q.d . ) mouth , without twice-daily ( b.i.d . ) RBV ( 200 mg capsule ; weight-based dosing ) . Participants relapse follow completion therapy Part A offer option retreatment 16 week MK-3682B RBV Part C ( data obtain Part C use analysis outcome measure ) .</brief_summary>
	<brief_title>Efficacy Safety Grazoprevir ( MK-5172 ) MK-3682 With Elbasvir ( MK-8742 ) Ruzasvir ( MK-8408 ) Chronic Hepatitis C Genotype ( GT ) 1 GT2 Infection ( MK-3682-011 )</brief_title>
	<detailed_description>In Part A , study therapy administer separate product , take q.d . mouth . In Part B Part C , participant take 2 MK-3682B FDC tablet q.d . mouth ; MK-3682B FDC tablet contain grazoprevir 50 mg + MK-3682 225 mg + ruzasvir 30 mg .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Parts A B : Previously untreated chronic HCV GT1 GT2 evidence nontypeable mixed genotype infection Has HCV ribonucleic acid ( RNA ) &gt; = 10,000 IU/mL peripheral blood time screening Has cirrhosis liver ( Part B ) noncirrhotic ( Part A B ) Is HCV treatment naïve ( define prior exposure interferon , ribavirin , approve experimental HCVspecific directacting antiviral agent ) Is non childbearing potential agrees avoid become pregnant impregnating partner begin least 2 week prior administration initial dose study drug either 14 day last dose study drug take RBV 6 month last dose study drug take RBV ( longer dictate local regulation ) . If abstinent heterosexual activity , participant Part A must use 2 acceptable form barrier contraception whereas participant Part B must use 2 acceptable form contraception may include oral contraceptive Part B : If coinfected human immunodeficiency virus ( HIV ) currently antiretroviral therapy ( ART ) plan initiate ART treatment participate study OR well control HIV ART ( ART regimen must contain follow antiretroviral medication : tenofovir , abacavir , lamivudine , emtricitabine , raltegravir , dolutegravir , rilpivirine dose modification change drug 4 week prior study entry [ Day 1 ] ) Has least one viable antiretroviral regimen alternative beyond current regimen event HIV virologic failure development antiretroviral drug resistance Parts A , B , C ( unless note otherwise ) : Has evidence decompensated liver disease manifest presence history ascites , esophageal gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease For cirrhotics ( Part B ) , participant ChildPugh Class B C PughTurcotte ( CPT ) score &gt; 5 , must exclude Is coinfected hepatitis B virus Is coinfected HIV ( Part A ) If coinfected HIV ( Part B ) , history opportunistic infection precede 6 month prior screen Has history malignancy &lt; =5 year prior sign inform consent except adequately treat basal cell squamous cell skin cancer situ cervical cancer carcinoma situ ; evaluation active suspect malignancy Has cirrhosis liver image within 6 month Day 1 show evidence hepatocellular carcinoma ( HCC ) evaluation HCC Has clinicallyrelevant drug alcohol abuse within 12 month screen Pregnant breastfeeding , expect conceive donate egg least 2 week prior Day 1 90 day last dose study medication , longer dictate local regulation Has follow condition : organ transplant ( include hematopoietic stem cell transplant ) cornea hair poor venous access precludes routine peripheral blood sampling required trial history gastric surgery ( e.g. , staple , bypass ) history malabsorption disorder ( e.g. , celiac sprue disease ) current history clinically significant cardiac abnormalities/dysfunction , include limited : angina , congestive heart failure , myocardial infarction , pulmonary hypertension , complex congenital heart disease , cardiomyopathy , significant arrhythmia , uncontrolled hypertension , history use antianginal antiarrhythmic agent cardiac condition , prolong ECG QTc interval ( &gt; 470 m male &gt; 480 m female Fridericia formula ) screen visit , personal family history Torsade de point chronic pulmonary disease , include limited : clinically significant chronic obstructive pulmonary disease , interstitial lung disease , pulmonary fibrosis , sarcoidosis central nervous system ( CNS ) trauma require intubation , intracranial pressure monitoring , brain meningeal skull surgery , result seizure , coma , permanent neurologic deficit , abnormal brain imaging , cerebral spinal fluid ( CSF ) leak . Prior brain hemorrhage and/or intracranial aneurysm ( whether adequately repair ) current , history , seizure disorder unless seizure &gt; 10 year ago , single isolated event , history current use antiseizure medication prescribe , normal neurological examination document trial file within 6 month Day 1 Has history stroke transient ischemic attack Has history medical/surgical condition result hospitalization within 3 month prior enrollment , minor elective procedure Has medical/surgical condition may result need hospitalization period study Has medical condition requiring , likely require , chronic systemic administration corticosteroid , TNF antagonists , immunosuppressant drug course trial condition , prestudy laboratory ECG abnormality history illness , , opinion investigator , might confound result study pose additional risk administer study drug subject lifethreatening SAE screen period evidence history chronic hepatitis cause HCV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , hemochromatosis , Wilson 's disease , α1antitrypsin deficiency , alcoholic liver disease , autoimmune hepatitis Parts B C : male whose female partner ( ) is/are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>